Kymera Therapeutics Inc logo

Kymera Therapeutics Inc(KYMR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
WEAK BUY
BUY for 16 days
PROFIT SINCE LAST BUY
-8.94% ▼
LAST CLOSE
$115.31
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for KYMR

11/20/2026: KYMR (3-star) is a REGULAR-BUY. BUY for 16 days. Simulated Profits (-8.94%). Updated daily EoD!

Kymera Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel small molecule protein degraders for immunology, inflammatory diseases, and oncology. The company's core strength lies in its proprietary Pegasus platform and a major co-development partnership with Sanofi, which together validate its scientific approach and provide essential funding. Its primary investment story centers on the potential of its pipeline—particularly lead assets like KT-474—to address large, underserved markets with first-in-class therapies. However, the company faces typical clinical-stage risks, including high R&D cash burn, lack of commercial product revenues, and intense biotechnology competition. Kymera is best suited for growth-oriented investors with a high risk tolerance who are willing to monitor key clinical trial readouts and partnership progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitKymera offers substantial long-term growth potential anchored by its innovative targeted protein degradation platform and broad clinical pipeline.
Momentum investorStrong fit while signal remains positiveThe stock often experiences sharp upward momentum driven by clinical data readouts and partnership developments.
Value investorWeak fitAs a pre-revenue clinical-stage biotech company with ongoing net losses, it lacks traditional value metrics like earnings or dividends.
Dividend investorWeak fitThe company does not pay dividends, directing all capital into research and clinical trial execution.
Low-risk investorWeak fitHigh clinical development risks and share price volatility make it unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience significant price swings based on trial results and market sentiment.
Valuation riskMedium / highValuations are heavily dependent on future pipeline success rather than current revenues or earnings.
Competition risk (targeted protein degradation)Medium / highThe competitive landscape in protein degraders is intensifying as multiple peers race to validate similar therapeutic targets.
Business qualityMediumThe company possesses a strong scientific platform and premier pharma backing, though commercial validation is still pending.
Dividend incomeLow / noneNo dividends are paid or expected in the near term.
Execution riskHighSuccessful clinical trial execution and regulatory approvals are critical for the company's long-term survival and valuation.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 9.84B USD
Price to earnings Ratio -
1Y Target Price 145.22
Price to earnings Ratio -
1Y Target Price 145.22
Volume (30-day avg) 930.9K shares
Beta 2.03
52 Weeks Range 63.69 - 142.92
Updated Date 11/21/2026
52 Weeks Range 63.69 - 142.92
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.64

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
60.2%
Active BUY / eligible
62 / 103
30-Day BUY Count Change
+18
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
46.2%
Active BUY / eligible
18 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 81%
Avg. Invested days 31
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
KYMR receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
KYMR has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-39.1%), weak cash generation (FCF margin -597.8%), negative revenue growth (-16.7%).

Financial Health Rating

★★★★★
KYMR's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 991.3% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
KYMR's growth profile is soft, with the least-weak measure being free-cash-flow growth at -13.0% FY2025 versus FY2024. By comparison, while revenue growth (-16.7%, negative) and earnings growth (-39.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 117.3% and approximately 80.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.07% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 14.47%
Baker Bros Advisors LP 10.14%
venBio Select Advisor LLC 8.76%
T. Rowe Price Associates, Inc. 8.33%
T. Rowe Price Investment Management,Inc. 7.33%

Unit Economics (Per $1K Revenue)

★★★★★
KYMR generates approximately $1,000 of gross profit, $-8,913 of operating income, and $-5,978 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.07%

Quantitative Style Profile

★★★★★
KYMR has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Licensing RevenueUpfront payments, research funding, and clinical milestone achievements from major pharmaceutical partners like Sanofi.Revenue is irregular and tied directly to partnership progress rather than commercial product sales.
Grants and Research FundingNon-dilutive funding from research grants or institutional awards supporting early-stage platform discovery.Provides minor supplemental funding while core operations are supported by equity financing and partner deals.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9.30B
Price to Sales(TTM) 96.29
Enterprise Value 9.30B
Price to Sales(TTM) 96.29
Enterprise Value to Revenue 90.97
Enterprise Value to EBITDA -9.49
Shares Outstanding 85.37M
Shares Floating 68.26M
Shares Outstanding 85.37M
Shares Floating 68.26M
Percent Insiders 2.07
Percent Institutions 117.3

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.